For ankle osteoarthritis, plantar fasciitis, and chronic Achilles tendinopathy, mesenchymal stem cell (MSC) therapy is an image-guided alternative to fusion, total ankle replacement, or repeated cortisone. Not every diagnosis qualifies: candidacy is decided on your imaging, read by the physician team.
For the ankle, the standard surgical answer is arthrodesis (fusion) or total ankle arthroplasty (replacement). Both are real options for end-stage disease. Patients with preserved tibiotalar joint space and a clear inflammatory driver are often worth evaluating first.
The foot and ankle are mechanical. Every step loads the joint, so the recovery curve is slower than knee or shoulder. The trade is durability: when therapy holds in this region, it tends to hold well. Ankle arthritis rarely sits alone: the tendons and ligaments that stabilize the joint are usually involved, and we treat those too, not just the joint surface.
If your foot and ankle surgeon has recommended fusion or replacement but your imaging still shows real joint space, an evaluation is a reasonable next step. We'll read your films and tell you plainly.
Ankle osteoarthritis, preserved tibiotalar joint space
Post-traumatic or primary ankle arthritis with cartilage wear but limited bone-on-bone. Often a recommendation for fusion is already on the table.
Soft-tissue and peri-bony foot pain
Refractory plantar fasciitis, Achilles tendinopathy or tendinosis, and posterior tibial tendon dysfunction. Calcific deposits or heel spurs with chronic inflammation, after splinting, physical therapy, eccentric loading, and cortisone or PRP.
Severe deformity, neuropathy-driven pain
Significant varus or valgus malalignment, Charcot foot, or neuropathic pain: surgery or offloading is the correct tool.
Every evaluation has the physician team reading your imaging and history. Not every diagnosis qualifies. Candidacy is decided on staging, structure, and your specific case.
Post-traumatic or primary tibiotalar osteoarthritis. Often a decade after an old sprain or fracture. Best response when joint space is preserved.
Ultrasound-guided injection for soft-tissue and peri-bony sites, where eccentric loading, shockwave therapy (ESWT), cortisone, or PRP have stopped holding.
Hallux rigidus with preserved motion, midfoot osteoarthritis. Painful push-off, limited dorsiflexion, surgery framed as the only option.
The ankle and forefoot demand precision, so image guidance is non-negotiable. Cells are delivered under fluoroscopy or high-resolution ultrasound, in-plane, with needle position confirmed before release. Off-loading instructions follow the patient home.
Joint cases like yours use bone-marrow and umbilical-cord MSCs, often in combination and sometimes with chondrocytes for cartilage support. The exact recipe (which cells, what doses, which routes) is decided by Celva's physician team after reviewing your imaging. Matched to your case, not pulled off a shelf. Why we use multiple cell types →
The entire procedure is physician-supervised at Hospital Angeles, Tijuana. A Celva driver brings you from San Diego; most patients are home the same day. A walking boot is provided for the first 48–72 hours when indicated.
A 15-minute call with a patient coordinator, who gathers whatever records you have. The physician team reviews joint space, alignment, and structural integrity on weight-bearing films and, where indicated, MRI. You'll hear either way, in writing.
Cell type and dose, delivery route, and the same-day systemic IV.
Fluoroscopy for the tibiotalar joint, high-resolution ultrasound for tendon and forefoot. Needle position confirmed before release. Local anesthetic, with twilight sedation available if you want it (no general), so you stay comfortable and still and the physician can place the cells precisely. 15 to 30 minutes.
A second MSC dose IV in the infusion suite. The IV and the injection are designed to work together. About 45 minutes, monitored.
The foot responds slower, so the later calls matter most: a pain-and-safety call at 1 week, then calls at 1, 3 and 6 months, then once a year, by phone or video, from your patient coordinator or aftercare specialist, with your walking protocol confirmed at each step. A physician joins when needed.
No outcome guarantees. What you get is a thorough evaluation, a realistic conversation, and treatment delivered to pharmaceutical-grade standards. Here is what foot & ankle candidates generally report.
Morning pain shorter, swelling reduced. Loaded pain often unchanged yet: the joint carries every step.
For most qualifying candidates, the distance comes back: farther before the pain, more of the day on your feet. Not everyone, and not all at once.
The foot is slower than the knee. Some patients keep improving past this point. Whether a second treatment makes sense is decided at your follow-up reviews.
Improvement can keep building through the first year. Body weight, footwear, and activity load affect how long results hold.
The foot and ankle take longer to respond than other regions. MSCs work through a slow paracrine process, and the joint never gets a real rest: you load it every step.
Your patient coordinator or aftercare specialist follows up at 1 week, then at 1, 3 and 6 months, then once a year, asking how far you walk before the pain. A physician joins when needed. You're not tracking this alone.
Not a guaranteed replacement, but a legitimate option to evaluate first. Patients with moderate tibiotalar OA still have joint structure to work with. End-stage disease with bone loss is considered case by case, after a frank forecast; severe malalignment is generally surgical. Candidacy is decided on weight-bearing imaging.
Foot & ankle is slower than other regions. Most patients notice change between 8 and 16 weeks, and improvement can keep building through the first year. The joint carries every step, which slows the response curve.
Refractory plantar fasciitis (after splinting, PT, ESWT, and cortisone or PRP) is a reasonable indication. We image the fascia first: degenerative thickening confirms a fasciopathy rather than acute inflammation. Acute or first-time plantar fasciitis should run conservative care first.
Sometimes. Plan on staying off the foot with very limited activity for the first 7 to 10 days. For tibiotalar and Achilles injections we typically also provide a walking boot for the first 48 to 72 hours and reintroduce normal footwear gradually. Forefoot and midfoot injections usually don't require a boot. You'll have a written off-loading protocol before you fly home.
These are mechanical deformities, not inflammatory or cartilage problems. MSC therapy doesn't realign bone. If pain is coming from associated first MTP OA, we can sometimes treat the joint while leaving the deformity. Pure deformity is a surgical question.
Your first call is with a Celva patient coordinator. Celva's physician team then reviews your imaging, history, and goals, and tells you plainly whether MSC therapy is a realistic option for your foot or ankle. If it isn't, we'll say so.
